Editas plots pipeline strategy in the wake of EDIT-101 halt

As Editas moves on from a lead program that left investors with doubts about the gene editing company’s technology and pipeline, the biotech’s new management team aims to make the most of an opportunity to craft a new strategy and right the company’s course.

Less than six months into the CEO role, Gilmore O’Neill has his sights on new applications for the company’s CRISPR gene editing technology, with plans to eventually branch out from Editas’ historical focus areas of ophthalmology and ex vivo editing, though he’s not yet making changes beyond the lead program...